CASTAGNA EUGENE A, President and COO, sold 25,000 shares of the Bed Bath & Beyond Inc. (NASDAQ:BBBY) in an exchange that happened on July 5th. The stock was sold at an average price of $20.81 per share, amounting to a transaction worth $520,348. The purchase was made public in a document filed with the SEC.
With this stock price’s latest movement, it is now -36.75% away from its 1-year high and 45.60% higher than its 1-year low price. In the past seven days, the stock price volatility for Bed Bath & Beyond Inc. was 7.77%, whereas its volatility in the past 30 days has been 6.18%. This public company’s stock also has a beta score of 0.94. When the beta value is less/more than 1, it can imply that the stock is less/more volatile than the wider stock market – a metric that traders will surely be keeping tabs on.
Bed Bath & Beyond Inc. (NASDAQ:BBBY) most recently published its quarterly earnings results. The firm posted $0.36 earnings per share (EPS) for the three-month period, missing analysts’ consensus estimate of $0.50 by $0.14. The publicly-traded organization reported revenue of $2,935.02 million for the quarter, compared to the average analyst forecast calling for $2,955.95 million, which was missing the analyst consensus estimate.
Shares of Bed Bath & Beyond Inc. (BBBY) surged 6.58%, amounting to a gain of $0.94 per share, to finish the regular trading session at $15.23 on Friday 01/11/2019. After beginning the session at $14.14, shares of Bed Bath & Beyond Inc. reached as high as $15.57 during the day, while hitting a 1-day low of $14.04. Trade volume reached 26,441,412 shares against this stock’s average daily volume of 5.92M shares, with a total float of 133.30M. As a consequence of the price increase, Bed Bath & Beyond Inc. now has a current market value of 2.04B.
Bristol-Myers Squibb Company (NYSE:BMY) added 0.57% to its trading price by the close of the most recent session, jumping from its previous closing price of $47.72 to $47.99. This stock decreased in value by 2.35% during the last 7-day period, and experienced a gain of -8.47% over the past 30-day period. In the past three months, this stock’s price lost by -21.03% , and subtracted -15.53% to its price during the last six months of trading. BMY demonstrated a yearly price loss of -22.61% , while its year-to-date (YTD) price performance has been down -7.68% . This stock’s price changed by +8.33% compared to its 90-day low, and moved down -19.04% comparing to its 90-day high price.
Have a quick look on short, medium and long-term indicators. According to the Composite Indicator, Trendspotter rated the BMY stock as “Sell”. In the short-term, Bristol-Myers Squibb Company (BMY) has a 20-day average volume of 17,308,176 shares and short-term indicators sets the BMY stock as “ 60% Sell ” on average basis. In the medium-term, BMY stock has a 50-Day average volume of 12,238,962 shares and medium-term indicators gave the average rating of “ 100% Sell ”, while in the long-term period the FB stock has a 100-Day average volume of 9,624,887 shares. On average, long-term indicators rated the stock as “100% Sell ”. The overall picture from all short, medium and long-term indicators sets the BMY stock as “88% Sell ” on average basis.
Recently, multiple brokerages have sent out reports on BMY. Citigroup, for example, Downgrade its rating on shares of Bristol-Myers Squibb Company from “Buy ” to a “ Neutral”according to a research note from Monday October 22nd, 2018. while giving the stock a “Neutral” rating, as stated in a research report from Tuesday, October 9th, 2018. Atlantic Equities, on the other hand, Upgrade a from “Underweight ” to “ Neutral” rating on this stock in a research note dated Wednesday, August 8th, 2018.
In other news related to Bristol-Myers Squibb Company stock, 74.84% shares of BMY held by institutions. The total number of institutions who held the BMY shares was 2,169, according to most recent SEC filling. During the past quarter, total 1,221,594,603 shares held by institutions with the net change of 8,367,267 shares. In the meantime, 129 new institutions bought the shares of Bristol-Myers Squibb Company for the first time and 73 institutions sold all their holdings in the company’s common stock. 801 institutions increased their investment in the BMY stock and 891 institutions decreased their investment in the Bristol-Myers Squibb Company (BMY)’s stock during the last quarter.